Annual Meeting Exclusive Interview | Dr. Xiong Ma: Comparing International and Chinese Guidelines for Autoimmune Hepatitis Treatment

2024.03.13
Autoimmune Hepatitis (AIH) is an acute or chronic liver inflammatory disease caused by unknown immune abnormalities. Without timely treatment, it can progress to liver cirrhosis, liver failure, and even lead to death. The diagnostic scoring systems and criteria proposed in current domestic and international guidelines have significantly advanced the diagnosis and treatment of AIH. Moreover, continuous progress in research on new strategies and medications for AIH treatment internationally and domestically offers valuable references for clinical diagnosis and treatment. At the 21st National Viral Hepatitis and Hepatology Academic Conference and the 2023 Annual Meeting of the Chinese Medical Association's Hepatology and Infectious Disease Branches, Dr. Xiong Ma from Renji Hospital affiliated with the Shanghai Jiao Tong University School of Medicine delivered a keynote report on the latest advancements in AIH diagnosis and treatment. He also provided an insightful analysis of the similarities and differences between international and Chinese treatment guidelines. In this exclusive interview, Dr. Ma discusses these topics, and we have compiled the content for our readers' benefit.
ABC7|Dr.Javier Cortes:Treatment directions and prospects for HER2+ advanced breast cancer treatment

ABC7|Dr.Javier Cortes:Treatment directions and prospects for HER2+ advanced breast cancer treatment

2024.02.26
HER2+ (HER2-positive) breast cancer is a type of breast cancer subtype with strong aggressiveness and poor prognosis. With the approval of more new targeted drugs for clinical application, the prognosis of HER2+ breast cancer patients continues to improve. In the absence of previous anti-HER2 targeted therapy, patients with HER2+ have a higher risk of recurrence. After anti-HER2 therapy, the risk of recurrence is significantly reduced. In recent years, the emergence of antibody-coupled (ADC) drugs has brought the treatment of HER2+ breast cancer patients into a new era, but there are still some unsolved problems. At the 7th International Consensus Conference on Advanced Breast Cancer (ABC7), Oncology Frontier invited Dr.Javier Cortes of the Vall d'Hebron Institute of Cancer in Barcelona, Spain, to summarize and look forward to the changes in the field of HER2+ advanced breast cancer.
ABC7 | Dr.Ginny Mason:Working together to help breast cancer patients recover

ABC7 | Dr.Ginny Mason:Working together to help breast cancer patients recover

2024.02.26
The decisions faced by cancer patients are often many and complex. At present, the doctor-patient co-decision model is widely used in cancer patients. At the 7th International Consensus Conference on Advanced Breast Cancer (ABC7) "Patient advocacy session: Complexities of shared decision making "featured experts discussing complexities of shared decision making among patients.Oncology Frontier invited Dr.Ginny Mason, the host of the show, to introduce the common psychological problems of breast cancer patients and how to deal with them.
Dr.Hu Xichun &Hope S. Rugo: Future treatment strategies for advanced triple-negative breast cancer and HR+/ HER2-breast cancer from the perspective of ADC drug treatment progress

Dr.Hu Xichun &Hope S. Rugo: Future treatment strategies for advanced triple-negative breast cancer and HR+/ HER2-breast cancer from the perspective of ADC drug treatment progress

2024.02.26
The International Consensus Conference on Advanced Breast Cancer (ABC) is the premier international conference in the academic field of advanced breast cancer, whose primary goal is to develop international consensus guidelines for the management of patients with advanced breast cancer. These guidelines are based on the latest evidence and can be used to guide treatment decisions in many different healthcare Settings around the world. The ABC also aims to identify research priorities based on the most important areas of unmet need, analyze and discuss existing data to provide the most accurate management recommendations, influence policymakers and funding agencies, and ultimately improve standards of care, survival, and quality of life. On the ABC7,Oncology Frontier invited Professor Hu Xichun, Affiliated Cancer Hospital of Fudan University, and Professor Hope S.Rugo, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, to present their views on the diagnosis and treatment concept of advanced triple-negative breast cancer and HR+/ HER2-breast cancer.
ESMO China Voice | Professor Bin Shao : Comprehensive Genomic Analysis of Advanced HR+/HER2- Breast Cancer Patients Using Liquid Biopsy

ESMO China Voice | Professor Bin Shao : Comprehensive Genomic Analysis of Advanced HR+/HER2- Breast Cancer Patients Using Liquid Biopsy

2024.02.23
HR+/HER2- is the most common subtype of breast cancer, accounting for approximately 65% to 70% of all breast cancer cases. Improving the survival benefits for patients with advanced HR+/HER2- breast cancer has always been a hot topic in this field and a unanimous goal for scholars and experts. Exploring the genomic characteristics of advanced HR+/HER2- breast cancer can enhance our understanding of it, and even identify potential biomarkers that affect its treatment and prognosis. The team led by Professor Li Huiping from the Peking University Cancer Hospital conducted a comprehensive genomic analysis of advanced HR+/HER2- breast cancer patients using liquid biopsy technology. Their research results were included as a poster (abstract number: 496P) at this year's ESMO conference. Oncology Frontier has specially invited Professor Shao Bin to introduce the latest results of this study.